Neurocrine Biosciences Restricted Cash remained flat by 0.0% to $8.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $8.00M to $8.00M.
An increase may signal higher debt service requirements or increased collateral obligations, while a decrease may indicate the release of restricted funds.
Cash balances that are legally or contractually set aside for specific purposes, such as debt service reserves, collater...
Common in capital-intensive industries like energy where project financing requires specific reserve accounts.
restricted_cash| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $371.20M | $314.30M | $278.00M | $171.10M | $7.80M | $111.60M | $168.20M | $8.00M | $8.00M | $8.00M | $8.00M | $8.00M | $8.00M | $8.00M | $8.00M |
| QoQ Change | — | -15.3% | -11.5% | -38.5% | -95.4% | >999% | +50.7% | -95.2% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | -53.9% | -97.5% | -59.9% | -1.7% | +2.6% | -92.8% | -95.2% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |